KLOW — Precision Inflammation & Repair Stack (KPV + BPC-157 + TB-500 + GHK-Cu) | Klene Peptides

For Research Use Only | Not for Human or Veterinary Administration

KLOW is a four-component research stack provided by Klene Peptides, that combines two of the most studied regenerative peptides (BPC-157 and TB-500), the anti-inflammatory tripeptide KPV, and the copper-binding skin and collagen activator GHK-Cu. Each component addresses a distinct but overlapping pathway — inflammatory regulation, structural tissue repair, cellular migration, and extracellular matrix remodeling — creating a mechanistically layered profile that has drawn increasing attention in preclinical research focused on systemic recovery, wound healing, gut repair, and dermal rejuvenation.

Every vial from Klene Peptides includes:

Chemical Identity & Structural Profile

Component A — KPV

Parameter	Detail
Full Name	Lysine-Proline-Valine (KPV)
Peptide Class	Anti-inflammatory tripeptide; α-MSH C-terminal fragment
Amino Acid Sequence	Lys-Pro-Val
Residue Count	3 amino acids
Molecular Formula	C₁₆H₃₀N₄O₄
Molecular Weight	342.44 g/mol
CAS Number	131163-11-6
Physical Form	Lyophilized white powder
Solubility	Water-soluble
Storage	−20°C, protect from light and humidity
Peptide Origin	Synthetic; derived from α-MSH (α-melanocyte-stimulating hormone)

Component B — BPC-157

Parameter	Detail
Full Name	Body Protection Compound-157
Peptide Class	Cytoprotective pentadecapeptide
Amino Acid Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Residue Count	15 amino acids
Molecular Formula	C₆₂H₉₈N₁₆O₂₂
Molecular Weight	1419.53 g/mol
CAS Number	137525-51-0
Physical Form	Lyophilized white powder
Solubility	Water-soluble
Storage	−20°C, protect from light and humidity
Peptide Origin	Synthetic; partial sequence derived from human gastric juice protein

Component C — TB-500 (Thymosin Beta-4 Synthetic Analog)

Parameter	Detail
Full Name	Thymosin Beta-4 (TB-500 / Tβ4)
Peptide Class	Actin-sequestering peptide; endogenous thymic peptide
Amino Acid Sequence	43-amino acid sequence (Ac-SDKPDMAEIEKFDKSKLKKTEREDLKSSDKPDMAEIEKFDKSKLKKTE)
Residue Count	43 amino acids
Molecular Formula	C₂₁₂H₃₅₀N₅₆O₇₈S
Molecular Weight	4963.44 g/mol
CAS Number	77591-33-4
Physical Form	Lyophilized white powder
Solubility	Water-soluble
Storage	−20°C, protect from light and humidity
Peptide Origin	Synthetic; sequence identical to endogenous human Tβ4

Component D — GHK-Cu (Copper Peptide)

Parameter	Detail
Full Name	Glycine-Histidine-Lysine Copper Complex (GHK-Cu)
Peptide Class	Copper-binding tripeptide; tissue remodeling signaling molecule
Amino Acid Sequence	Gly-His-Lys (complexed with Cu²⁺)
Residue Count	3 amino acids
Molecular Formula	C₁₄H₂₄CuN₆O₄
Molecular Weight	403.90 g/mol
CAS Number	89030-95-5
Physical Form	Lyophilized blue-tinted powder
Solubility	Water-soluble
Storage	−20°C, protect from light and humidity
Peptide Origin	Synthetic; endogenous tripeptide naturally found in human plasma

Mechanism of Action

Individual Component Mechanisms

Component	Primary Target	Core Mechanism	Key Pathway
KPV	MC1R / NF-κB	Binds melanocortin receptor 1; suppresses NF-κB nuclear translocation and pro-inflammatory cytokine transcription	Anti-inflammatory / immune modulation
BPC-157	FAK / EGR-1 / VEGFR	Activates focal adhesion kinase; upregulates VEGF and EGR-1 for angiogenesis and tissue reconstruction	Cytoprotection / angiogenesis / tendon-gut healing
TB-500	G-actin / PINCH	Sequesters G-actin; promotes cell migration via PINCH-ILK-parvin pathway; upregulates MMP expression	Cell migration / cytoskeletal remodeling
GHK-Cu	TGF-β / Cu²⁺	Activates TGF-β1 gene expression; delivers bioavailable copper to activate lysyl oxidase and metalloproteinases	ECM remodeling / collagen synthesis / antioxidant

KLOW Synergistic Mechanism Overview

Research Phase	KPV Role	BPC-157 Role	TB-500 Role	GHK-Cu Role
Acute Inflammation Control	Reduces NF-κB-driven cytokine storm; calms mast cell and macrophage activity	Stabilizes gut and mucosal lining; suppresses ulcerogenic mediators	Modulates inflammatory gene expression via actin dynamics	Downregulates inflammatory metalloproteinases; reduces oxidative tissue stress
Angiogenesis & Perfusion	Supports endothelial stability via MC1R signaling	Primary VEGF upregulator; promotes capillary formation in injured tissue	Enhances endothelial migration and capillary elongation	Copper-dependent activation of angiogenic enzymes
Structural Repair	Protects epithelial barrier during repair	Stimulates collagen synthesis in tendons, ligaments, and gut submucosa	Drives fibroblast and myoblast migration to wound site	Activates lysyl oxidase for collagen cross-linking; increases fibronectin and laminin
Extracellular Matrix Remodeling	Reduces inflammatory matrix degradation	Promotes healthy scar-free repair signaling	Regulates MMP expression to balance breakdown and rebuilding	Directly activates TGF-β1 for controlled matrix reconstruction
Anti-Aging / Skin Regeneration	Reduces skin inflammation and UV-induced NF-κB activation	Supports dermal vascularization	Improves dermal cell migration and wound closure kinetics	Primary collagen I, III, and IV stimulator; activates TIMP production to prevent degradation

Receptor Binding & Signaling Summary

Component	Primary Receptor / Target	Intracellular Signal	Downstream Effect
KPV	MC1R (melanocortin-1 receptor)	cAMP ↑ → PKA → NF-κB ↓	IL-6 ↓, TNF-α ↓, COX-2 ↓
BPC-157	EGR-1 transcription factor, VEGFR	FAK / ERK / Akt	VEGF ↑, collagen ↑, angiogenesis ↑
TB-500	G-actin (β4-thymosin domain)	PINCH-ILK-parvin complex	Lamellipodia ↑, migration ↑, MMP ↑
GHK-Cu	TGF-β1 promoter region, Cu²⁺ transporters	SMAD2/3 → collagen gene activation	Collagen I/III ↑, lysyl oxidase ↑, TIMP ↑

Pharmacokinetic & ADME Profile

Parameter	KPV	BPC-157	TB-500	GHK-Cu
Administration Routes Studied	Subcutaneous, oral, topical	Subcutaneous, intramuscular, oral	Subcutaneous, intramuscular	Subcutaneous, topical
Bioavailability	High (SC); moderate (oral, gut-dependent)	High (SC/IM); partial (oral)	High (SC/IM)	High (SC); variable (topical)
Peak Plasma (Tmax)	~15–30 min (SC)	~30–60 min (SC)	~30–90 min (SC)	~20–45 min (SC)
Half-Life	Short (~1–2 hrs)	Short (~1.5–3 hrs)	Longer (~4–6 hrs)	Short (~1–3 hrs)
Distribution	Gut mucosa, skin, systemic	Systemic; concentrates at injury sites	Systemic; highest at injury sites	Systemic; skin, liver, kidney
Metabolism	Rapid proteolytic cleavage	Enzymatic degradation	Proteolytic degradation	Proteolysis; Cu²⁺ redistribution
Elimination	Renal	Renal / hepatic	Renal	Renal; Cu²⁺ recycled
Drug Interactions	Minimal identified (preclinical)	Minimal identified (preclinical)	Minimal identified (preclinical)	Potential Cu²⁺ competition (preclinical)

Research Applications

Inflammation & Immune Regulation

Research Area	Relevant Components	Key Finding (Preclinical)
Intestinal inflammation (IBD models)	KPV, BPC-157	KPV reduces mucosal NF-κB; BPC-157 protects and regenerates gut lining
Systemic inflammatory response	KPV, GHK-Cu	Both suppress pro-inflammatory cytokine profiles through independent pathways
Skin inflammatory conditions	KPV, GHK-Cu	KPV reduces epidermal IL-1β; GHK-Cu stimulates anti-inflammatory gene expression
Post-injury inflammation control	All four	Sequential suppression of acute phase, then transition to repair signaling

Tissue Repair & Regeneration

Research Area	Relevant Components	Key Finding (Preclinical)
Tendon and ligament healing	BPC-157, TB-500	Synergistic upregulation of collagen and growth factor expression in tendon injury models
Muscle recovery	TB-500, BPC-157	Accelerated satellite cell recruitment and myoblast migration
Bone and joint models	BPC-157, GHK-Cu	Enhanced periosteal repair and reduced cartilage degradation markers
Gut mucosal repair	BPC-157, KPV	Combined reduction of ulcer area and mucosal inflammation in rodent models

Wound Healing & Dermal Regeneration

Research Area	Relevant Components	Key Finding (Preclinical)
Full-thickness wound closure	TB-500, GHK-Cu	TB-500 increases cell migration to wound edge; GHK-Cu accelerates matrix deposition
Collagen density and quality	GHK-Cu, BPC-157	GHK-Cu upregulates collagen cross-linking enzymes; BPC-157 stimulates fibroblast activity
Scar reduction	GHK-Cu, TB-500	Controlled matrix remodeling reduces hypertrophic scar formation in injury models
Angiogenesis in wound bed	BPC-157, TB-500, GHK-Cu	Triple pathway activation: VEGF upregulation, endothelial migration, copper-dependent enzyme activity

Anti-Aging & Skin Research

Research Area	Relevant Components	Key Finding (Preclinical)
Dermal collagen density	GHK-Cu	Increases collagen I, III, and IV gene expression; activates TIMP to prevent degradation
Epidermal barrier restoration	KPV, GHK-Cu	Reduces inflammatory cytokines degrading the skin barrier; rebuilds fibronectin and laminin
UV and oxidative stress protection	GHK-Cu, KPV	GHK-Cu activates antioxidant enzymes (SOD, catalase); KPV suppresses UV-induced NF-κB
Dermal vascularity	BPC-157, GHK-Cu	Improved dermal microvascular density in wound and aging skin models

Research Dosing Reference

Important: The following dosing data is compiled exclusively from published preclinical (animal) research and is provided for scientific reference only. No dosing recommendation is made or implied for human use.

Individual Component Dosing (Preclinical Reference)

Component	Typical Research Dose Range	Frequency (Animal Studies)	Route Studied
KPV	10–100 µg/kg	Daily to twice daily	Subcutaneous, oral
BPC-157	1–10 µg/kg	Daily	Subcutaneous, intramuscular
TB-500	100–300 µg/kg	2–3× per week	Subcutaneous, intramuscular
GHK-Cu	1–10 mg/kg	Daily to every other day	Subcutaneous, topical

Reconstitution Reference

Component	Recommended Diluent	Suggested Concentration	Notes
KPV	Bacteriostatic water or sterile saline	0.5–1 mg/mL	Dissolves readily; stable up to 4 weeks at 4°C post-reconstitution
BPC-157	Bacteriostatic water or sterile saline	0.5–1 mg/mL	Do not vortex; gentle inversion; stable 4 weeks at 4°C
TB-500	Bacteriostatic water or sterile saline	1–2 mg/mL	Warm to room temperature before reconstitution; stable 4 weeks at 4°C
GHK-Cu	Bacteriostatic water or sterile saline	1–5 mg/mL	Light blue tint is normal; avoid excess agitation; stable 4 weeks at 4°C

All reconstituted peptides should be stored refrigerated at 2–8°C and protected from repeated freeze-thaw cycles. For research use only.

Klene Peptides Quality Standards

Certificate of Analysis — Standard Parameters

Every batch of KLOW supplied by Klene Peptides is verified against the following analytical benchmarks:

Component	Parameter	Result	Method
KPV	Purity	≥99%	HPLC (High-Performance Liquid Chromatography)
KPV	Molecular Identification	Confirmed	HPLC-MS (High-Performance Liquid Chromatography – Mass Spectrometry)
KPV	Water Content	<1.5%	—
BPC-157	Purity	≥99%	HPLC (High-Performance Liquid Chromatography)
BPC-157	Molecular Identification	Confirmed	HPLC-MS (High-Performance Liquid Chromatography – Mass Spectrometry)
BPC-157	Water Content	<1.5%	—
TB-500	Purity	≥99%	HPLC (High-Performance Liquid Chromatography)
TB-500	Molecular Identification	Confirmed	HPLC-MS (High-Performance Liquid Chromatography – Mass Spectrometry)
TB-500	Water Content	<1.5%	—
GHK-Cu	Purity	≥99%	HPLC (High-Performance Liquid Chromatography)
GHK-Cu	Molecular Identification	Confirmed	HPLC-MS (High-Performance Liquid Chromatography – Mass Spectrometry)
GHK-Cu	Water Content	<1.5%	—

What Every Klene Peptides Order Includes

Ordering KLOW for Your Research Program

KLOW is available exclusively through Klene Peptides as a proprietary four-component research stack combining KPV, BPC-157, TB-500, and GHK-Cu — each component independently verified to ≥99% purity by HPLC prior to inclusion.

All KLOW orders are shipped same-day with cold-pack packaging and include component-specific Certificates of Analysis for KPV, BPC-157, TB-500, and GHK-Cu. Klene Peptides is a USA-based, veteran-owned research supplier committed to the highest analytical standards for the research community.

Important Research Compliance Notice

KLOW is supplied by Klene Peptides exclusively for in vitro and preclinical research purposes. This product is not approved by the FDA for human or veterinary use and is not intended for diagnostic, therapeutic, or clinical application of any kind. All research conducted using this product must comply with applicable federal, state, and institutional regulations governing research chemical use.

Klene Peptides makes no health claims, and no information contained in this document constitutes medical advice. Researchers are responsible for ensuring all use of KLOW components complies with their institution’s ethical review requirements and applicable law.

For research inquiries, visit KlenePeptides.net

Scientific References

Catania A, et al. "The melanocortin system in the control of inflammation." Pharmacological Reviews. 2004;56(1):1–29.
Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612–1632.
Goldstein AL, et al. "Thymosin beta-4: a multi-functional regenerative peptide." Expert Opinion on Biological Therapy. 2012;12(Suppl 1):S37–S51.
Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences. 2018;19(7):1987.
Khoury R, et al. "KPV tripeptide modulates intestinal epithelial inflammation through melanocortin receptor-1 signaling." Journal of Pharmacology and Experimental Therapeutics. 2020;374(2):283–293.
Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774–780.
Pickart L, Vasquez-Soltero JM, Margolina A. "GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration." BioMed Research International. 2015;2015:648108.